Sign In
Buy TBPH
$16.86
+0.0100 (+0.0593%)
At Close: Jul 31, 2026
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
01:10pm, Tuesday, 14'th May 2024
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
06:58pm, Monday, 13'th May 2024
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Monday, 13'th May 2024
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Monday, 13'th May 2024
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 09'th May 2024
DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, Ma
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
06:00am, Monday, 29'th Apr 2024
DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 1
BTIG Research Predicts Over 118% Rally for These 3 Stocks
02:19pm, Monday, 15'th Apr 2024
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
08:51am, Monday, 15'th Apr 2024
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM E
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
12:36pm, Wednesday, 27'th Mar 2024
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
03:59pm, Tuesday, 12'th Mar 2024
The life of a bearish speculator can be dangerous and that's part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others' mise
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
12:51pm, Tuesday, 27'th Feb 2024
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
09:52pm, Monday, 26'th Feb 2024
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
06:26pm, Monday, 26'th Feb 2024
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Monday, 26'th Feb 2024
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to
